This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Astaxanthin
- DrugBank Accession Number
- DB06543
- Background
Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. It is found in the majority of aquatic organisms with red pigment. Astaxanthin has shown to mediate anti-oxidant and anti-inflammatory actions. It may be found in fish feed or some animal food as a color additive.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Astaxanthin (DB06543)
- Weight
- Average: 596.852
Monoisotopic: 596.386560154 - Chemical Formula
- C40H52O4
- Synonyms
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UNF-kappa-B inhibitor alpha Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Astaxanthin. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Astaxanthin. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Astaxanthin. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Astaxanthin. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bio-Life Astaxanthin 4mg Capsules Capsule 4 mg Oral BIO-LIFE MARKETING SDN. BHD. 2018-06-28 2018-11-22 Malaysia 
STAZEN Natural Astaxanthin Capsule, gelatin coated 4 mg Oral MCDEE SDN. BHD. 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bio Sun Astaxanthin (1.5 mg/15g) + Ascorbic acid (1.5 mg/15g) + Nicotinamide (4.5 mg/15g) + Ubidecarenone (3 mg/15g) Stick Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US 
GNC Multivitamin Mega Women Tablet Astaxanthin (25 mcg) + Ascorbic acid (100 mg) + Biotin (150 mcg) + Boron (1 mg) + Calcium (250 mg) + Cholecalciferol (800 IU) + Choline (5 mg) + Chromium (60 mcg) + Copper (1 mg) + Cryptoxanthin (5 mcg) + Cyanocobalamin (25 mcg) + Folic acid (200 mcg) + Grape seed oil (0.5 mg) + Green tea leaf (7 mg) + Hyaluronic acid (0.5 mg) + Inositol (5 mg) + Iodine (75 mcg) + Iron (9 mg) + Lipoic acid (12.5 mg) + Lutein (1 mg) + Lycopene (0.5 mg) + Magnesium (25 mg) + Manganese cation (1 mg) + Molybdenum (37.5 mcg) + Niacin (25 mg) + Pantothenic acid (25 mg) + Phylloquinone (40 mcg) + Pyridoxine (25 mg) + Riboflavin (25 mg) + Selenium (100 mcg) + Silicon dioxide (2 mg) + Thiamine (25 mg) + Turmeric (250 mcg) + Vanadium (5 mcg) + Vitamin A (2500 IU) + Vitamin E (15 IU) + Zeaxanthin (200 mcg) + Zinc (7.5 mg) + gamma-Aminobutyric acid (0.5 mg) Tablet Oral GNC LIVEWELL MALAYSIA SDN. BHD. 2020-09-08 Not applicable Malaysia Lifestream Astazan Capsule Astaxanthin (4 mg) + Lutein (40 mcg) + Vitamin E (10 mg) Capsule Oral CAREMARK SDN. BHD. 2020-09-08 2024-06-28 Malaysia VitaHealth L-Glutathione Plus Astaxanthin (1 mg) + Ascorbic acid (125 mg) + Cysteine (100 mg) + Glutathione (100 mg) + Lipoic acid (25 mg) + Zinc (2.5 mg) Tablet Oral VITAHEALTH BIOTECH SDN BHD 2019-10-03 2021-09-10 Malaysia
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as xanthophylls. These are carotenoids containing an oxygenated carotene backbone. Carotenes are characterized by the presence of two end-groups (mostly cyclohexene rings, but also cyclopentene rings or acyclic groups) linked by a long branched alkyl chain. Carotenes belonging form a subgroup of the carotenoids family. Xanthophylls arise by oxygenation of the carotene backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Tetraterpenoids
- Direct Parent
- Xanthophylls
- Alternative Parents
- Cyclohexenones / Secondary alcohols / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homomonocyclic compound / Carbonyl group / Cyclic ketone / Cyclohexenone / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound / Organooxygen compound
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- carotenone, carotenol (CHEBI:40968) / C40 isoprenoids (tetraterpenes), Carotenoids (C08580) / C40 isoprenoids (tetraterpenes) (LMPR01070263)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8XPW32PR7I
- CAS number
- 472-61-7
- InChI Key
- MQZIGYBFDRPAKN-UWFIBFSHSA-N
- InChI
- InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1
- IUPAC Name
- (6S)-6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-2,4,4-trimethylcyclohex-2-en-1-one
- SMILES
- C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002204
- KEGG Compound
- C08580
- PubChem Compound
- 5281224
- PubChem Substance
- 347827776
- ChemSpider
- 4444636
- 18451
- ChEBI
- 40968
- ChEMBL
- CHEMBL1255871
- ZINC
- ZINC000100042059
- PDBe Ligand
- AXT
- Wikipedia
- Astaxanthin
- PDB Entries
- 1gka / 6zzx / 8c18 / 8i34
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Recruiting Treatment Community Acquired Pneumonia (CAP) 1 somestatus stop reason just information to hide 2 Completed Treatment NPDR - Non Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus 1 somestatus stop reason just information to hide 2 Completed Treatment Osteoarthritis of the Knee 1 somestatus stop reason just information to hide 2 Enrolling by Invitation Treatment Amyotrophic Lateral Sclerosis (ALS) 1 somestatus stop reason just information to hide 2, 3 Terminated Treatment Joint Inflammation / Osteoarthritis Knees Both / Osteoarthritis of the Knee 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Not applicable 1 kg/1kg Stick Cutaneous Capsule Oral 4 mg Tablet Oral Capsule, gelatin coated Oral 4 mg Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000667 mg/mL ALOGPS logP 7.4 ALOGPS logP 8.05 Chemaxon logS -6 ALOGPS pKa (Strongest Acidic) 13.07 Chemaxon pKa (Strongest Basic) -3.5 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 74.6 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 195.98 m3·mol-1 Chemaxon Polarizability 73.77 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 273.8164575 predictedDarkChem Lite v0.1.0 [M-H]- 330.7718575 predictedDarkChem Lite v0.1.0 [M-H]- 260.60953 predictedDeepCCS 1.0 (2019) [M+H]+ 274.5865575 predictedDarkChem Lite v0.1.0 [M+H]+ 334.1148575 predictedDarkChem Lite v0.1.0 [M+H]+ 262.5043 predictedDeepCCS 1.0 (2019) [M+Na]+ 274.2312575 predictedDarkChem Lite v0.1.0 [M+Na]+ 331.2258575 predictedDarkChem Lite v0.1.0 [M+Na]+ 268.5961 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals (PubMed:1493333, PubMed:36651806, PubMed:7479976). On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription (PubMed:7479976, PubMed:7628694, PubMed:7796813, PubMed:7878466)
- Specific Function
- Enzyme binding
- Gene Name
- NFKBIA
- Uniprot ID
- P25963
- Uniprot Name
- NF-kappa-B inhibitor alpha
- Molecular Weight
- 35608.65 Da
References
- Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, Lee SK, Kim YM: Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells. 2003 Aug 31;16(1):97-105. [Article]
Drug created at March 19, 2008 16:36 / Updated at September 28, 2021 21:54